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Abstract  33 
 34 
Plants contain a wide range of non-nutritive phytochemicals, many of which have protective 35 
or preventive properties for human diseases. The aim of the present work has been to investigate the 36 
nutraceutical properties of sweet chestnut flour extracts obtained from fruits collected from 7 37 
geographic areas of Tuscany (Italy), and their ability in modulating skeletal muscle atrophy. We 38 
found that the cultivars from different geographic areas are characterized by composition and 39 
quantity of various nutrients and specific bioactive components, such as tocopherols, polyphenols 40 
and sphingolipids. The nutraceutical properties of chestnut sweet flours have been evaluated in 41 
C2C12 myotubes induced to atrophy by serum deprivation or dexamethasone. We found that the 42 
pretreatment with both total extract of tocopherols and sphingolipids is able to counterbalance cell 43 
atrophy, reducing the decrease in myotube size and myonuclei number, and attenuating protein 44 
degradation and the increase in expression of MAFbx/atrogin-1 (a muscle-specific atrophy marker). 45 
By contrast, polyphenol extracts were not able to prevent atrophy. Since we also found that -46 
tocopherol is the major form of tocopherol in sweet flour and its content differs depending on the 47 
procedure of sweet flour preparation, the mechanisms by which -tocopherol as well as 48 
sphingolipids affect skeletal muscle cell atrophy have been also investigated. This is the first 49 
evidence that chestnut sweet flour is a natural source of specific bioactive components with a 50 
relevant role in the prevention of cell degeneration and maintaining of skeletal muscle mass, 51 
opening important implications in designing appropriate nutritional therapeutic approaches to 52 
skeletal muscle atrophy.  53 
54 
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 Introduction 55 
Fruits and vegetables contain vitamins, minerals, fiber and potentially bioactive compounds 56 
known as phytochemicals. These compounds are not considered as nutrients but have protective or 57 
preventive properties for a variety of human diseases including cancer
1 
cardiovascular diseases
2
 and 58 
Alzheimer’s disease3 , mostly due to antioxidant and/or anti-inflammatory activities. Recent studies 59 
performed on Portuguese cultivars
4-6
 and Croatian cultivars of Castanea Sativa Mill extracts
7
 and 60 
on Mugello's marrons (Tuscany, Italy)
8,9
 have evidenced chestnuts and marrons as an important 61 
natural source of antioxidants, particularly of polyphenols and vitamin E. 62 
Polyphenols are the biggest group of phytochemicals that contribute to important 63 
characteristics of food such as taste, odor, colour and oxidative stability
10
. 64 
Many studies including epidemiological data suggest that long term consumption of food 65 
rich in plant polyphenols offers some protection against the principal chronic diseases, such as 66 
cancer, cardiovascular diseases, and neurodegenerative diseases
10
, mainly related to oxidative stress 67 
response
11
. Vitamin E is a generic term for all tocopherol and tocotrienol derivatives. The most 68 
abundant form of vitamin E isoforms in mammals is α-tocopherol and it has long been recognized 69 
as a classic free radical scavenging antioxidant whose deficiency impairs mammalian fertility
12
. 70 
New biological activities including anti-inflammatory, antineoplastic, and natriuretic functions have 71 
been reported for other tocopherols, such as γ-tocopherol12. In particular, the tocotrienol subfamily 72 
of natural vitamin E possesses powerful neuroprotective, anticancer, and cholesterol-lowering 73 
properties; for example, nanomolar concentration of -tocotrienol, but not of α-tocopherol, prevents 74 
neurodegeneration
13
. Epidemiological data suggest that γ-tocopherol is a better negative risk factor 75 
for certain types of cancer and myocardial infarction than is a α-tocopherol1, 12, 14.  76 
Oxidative stress induces unloading-mediated muscle atrophy that is prevented by 77 
polyphenols
15
. In addition, Vitamin E is a nutrient widely used to attenuate muscle injury associated 78 
with eccentric exercise
16
. 79 
Sphingolipids (SLs), components of the membranes of all eukariotic cells, participate in the 80 
control of a variety of important cell functions, such as cell growth, differentiation, inflammation, 81 
and apoptosis
17,18
. The first evidence of SL importance as functional nutrients was obtained by 82 
Merrill’s group (reviewed in17) that reported that dietary sphingomyelin (SM) inhibits colon 83 
carcinogenesis in animal models. In addition, other studies have shown that consumption of SLs 84 
reduces serum low-density lipoprotein cholesterol and elevates high-density lipoproteins
17
. SLs are 85 
found in all foodstuff; however, only a few of the published studies reported the analysis of their 86 
content in food, found to be some hundreds of mg/kg, a relatively low concentration
17
.
 
Degradation 87 
of the most abundant SLs, SM, by the action of several sphingomyelinases generates ceramide that 88 
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can also be formed from serine by de novo synthesis. Deacylation of ceramide leads to the 89 
formation of sphingosine that can be further phosphorylated by sphingosine kinases (SK) to yield 90 
sphingosine 1-phosphate (S1P)
18
. Among bioactive SLs, S1P acts as survival and trophic factor, 91 
increases cell proliferation and differentiation and inhibits apoptosis
18
. Recently, it has been 92 
demonstrated that SK1/S1P axis promotes myoblast differentiation
19
, exerts a trophic action on 93 
denervated or damaged skeletal muscle fibres
19-20
 and it is crucial for satellite cell activation and 94 
tissue regeneration
20-22
.  95 
Skeletal muscle exhibits great plasticity in response to altered activity levels, ultimately 96 
resulting in substantial changes in tissue mass: an increase have been associated with resistance 97 
exercise or after anabolic agent administration, whereas a loss in skeletal muscle mass (atrophy) has 98 
been observed in several conditions, such as starvation, ageing and physical inactivity, as well as in 99 
disease states including cancer cachexia, diabetes and AIDS
23,24
. At present effective treatments that 100 
can prevent, attenuate or reverse muscle atrophy are not clearly defined. Emerging evidence 101 
implicates oxidative stress as a key regulator of cell signaling pathways, leading to increased 102 
proteolysis and muscle atrophy during periods of prolonged disuse 
23
. The discovery of two muscle-103 
specific E3 ubiquitin ligases, Muscle atrophy F-Box (MAFbx/ atrogin-1) and Muscle RING (Really 104 
Interesting New Gene) Finger-1 (MuRF1), prompted renewed expectation in identifying muscle-105 
specific targets for therapeutic manipulation
24
, as the two enzymes belong to the ubiquitin 106 
proteasome pathway, the predominant pathway involved in protein degradation in skeletal muscle. 107 
Autophagy is also involved in skeletal muscle homeostasis: it can be detrimental and 108 
contribute to tissue degeneration, but can also be a compensatory mechanism for cell survival 
25
. 109 
Autophagy is characterized by sequestration of cytoplasmic components in double-membraned 110 
autophagosomes and their fusion with lysosomes. Autophagosomal membrane nucleation is 111 
promoted by phosphatidylinositol-3-phosphate generated by the Beclin-1-interacting complex
25
.  112 
The aim of the present work has been to investigate the nutraceutical properties of sweet 113 
chestnut flour extracts obtained from fruits of seven different areas of Tuscany and to examine 114 
whether these extracts could modulate skeletal muscle cell atrophy in C2C12 myotubes, reported to 115 
be a good model for the study of skeletal muscle cell biology
19, 26-28
.  116 
117 
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 Results  118 
 119 
Composition of tuscan chestnut flour. Content of bioactive molecules 120 
 121 
Since chestnut flour from Mugello area is obtained  essentially from a single cultivar 122 
(Marrone Fiorentino) (Table 1), we used this sample for the chemical  composition of this tuscan 123 
chestnut flour.   Sweet chestnut flour was analysed and characterized for the content of proteins, fat, 124 
carbohydrates and ions. Data reported in Table 2 indicate that the four has an high content of 125 
carbohydrates, starch being the most representative and similar in content to Spanish chestnut 126 
cultivars
39
. Previous studies on Spanish and Portuguese chestnut cultivars showed a protein content 127 
of 4.9-7.4 g/100 g dry weight, a higher value respect to that reported in Table 2
40
. Moreover, in the 128 
same study the content of fat (1.7-3.1 g/100g dry weight) is lower of that found in Marrone 129 
Fiorentino. The high content of complex carbohydrates, associated with the low content of fat, 130 
makes the chestnut flour a healthy food representative of the Meditteranean diet. The chemical 131 
composition in metals was not significantly different from what previously reported
6
. From a 132 
nutritional point of view, chestnut flour can be an important source of minerals: potassium is 133 
present in a significant concentration as well as magnesium and calcium.  134 
In order to investigate the nutraceutical properties of chestnut flour, the relative values of 135 
polyphenols, tocopherols and “functional” SLs were quantified (Table 3). Polyphenols vary from 136 
1688 to 2799 mg/Kg as (gallic acid), whereas the content in SLs, similar in all the samples, ranges 137 
from 48 to 56 mg/Kg dry weight. Chromatographic analysis revealed the presence of several 138 
vitamin E isoforms. γ-Tocopherol was the major tocopherol; the profile was similar along all the 139 
assayed tuscan sweet chestnut flours (γ-tocopherol >>> δ-tocopherol > α-tocopherol). Tocopherol 140 
content, ranging from 18 to 114 mg/Kg, appears to be dependent from several parameters: the 141 
drying method (traditional vs other not traditional), cultivar tipology and geographic locations in the 142 
same area.  143 
 144 
Effect of total polyphenol and tocopherol extracts on skeletal muscle cell growth  145 
 146 
The effects of total polyphenol and tocopherol extracts on cell growth and viability have been 147 
quantified both by cell counting and MTS assay, a method that measures the ability of 148 
dehydrogenases in living cells to reduce MTS to formazan (Fig. 1). Both tocopherol and polyphenol 149 
extracts decrease cell growth in a time-dependent manner compared to control cells, but 150 
polyphenols have a more-pronounced effect than tocopherols. Of note, the cell number at day 4 is 151 
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not significantly different from day 1 in cells treated with tocopherol extract and only slightly with 152 
polyphenol extract (Fig.1A). The difference is more evident after four days of culture, when MTS 153 
reduction capability is reduced by polyphenol or tocopherol extract to 12% and 50% of the control 154 
cells,  respectively (Fig.1B). Therefore, the  reduction of formazan formation  might be due either to 155 
a low number of cells metabolizing the MTS  and to a decrease of mitochondrial activity in each 156 
cell. 157 
Since polyphenol and tocopherol extract interfered with cell growth, we evaluated the ability of 158 
both compounds to induce cell death by lactate dehydrogenase (LDH) assay. The slight effect of 159 
tocopherol and polyphenol extracts in releasing LDH activity into cell medium at 4 days of 160 
incubation (7±3% and 10±3%, respectively) compared with the effect of 0.1% Triton X100 (set to 161 
100%) and the absence of apoptotic markers expression (cytosolic cytochrome C and mitochondria-162 
associated Bax) at the concentration used (data not shown), indicate the lack of cytotoxicity, 163 
suggesting that C2C12 myoblasts likely undergo cell cycle arrest and, presumably, start the 164 
myogenic program. 165 
 166 
Effect of total polyphenol and tocopherol extracts on starvation- and Dexa-induced muscle atrophy 167 
 168 
In order to investigate the involvement of functional molecules identified in chestnut flour on 169 
skeletal muscle cell atrophy, we used C2C12 myoblasts, a well known cell model for studying 170 
myogenesis induction
19
, the biology of terminal myogenic differentiated cells, and cell 171 
atrophy/hypertrophy. The contrast-phase images of C2C12 muscle myoblasts induced to 172 
differentiate as described in Methods is reported in Supplemental data (Fig 2). Myogenic 173 
differentiation is characterized by consistent and progressive modifications of cellular morphology 174 
such as tendency to single myoblast to elongate and fuse leading to the formation of syncytia with 175 
more nuclei (myotube) and modifications of the protein expression pattern with the appearance of 176 
typical protein markers of myogenic differentiation, such as sarcomeric actin, caveolin-3
19
, 177 
phospho-p38 MAPK and the nuclear translocation of the transcription factor, myogenin
20
 178 
(Supplemental data). Following atrophy induction by serum starvation or treatment with Dexa, as 179 
reported in supplemental data, C2C12 myotubes show a clear modification of cell morphology with 180 
a significant decrease in myotube size. It is worthy to note a significant decrease to a third and to a 181 
half of the control value after treatment with 24 nM total polyphenol and tocopherol extracts, 182 
respectively. While 4 nM tocopherol does not have any significant effect, 4 nM polyphenol extract 183 
is still able to significantly reduce cell size. 184 
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Interestingly, the incubation with total polyphenol extract did not prevent the reduction of 185 
the cellular diameter elicited by Dexa or serum starvation (Table 4), whereas the pre-treatment with 186 
tocopherols is able to revert the atrophic phenotype measured as cellular diameter as well as 187 
myonuclei number. Table 4 also shows, as a positive control, the effect of protein synthesis 188 
inhibitor cycloheximide (3 M), that promotes cell size and micronuclei number decrease, similarly 189 
to what observed with serum starvation and Dexa treatment. 190 
In another set of experiments we have investigated the modifications on cell atrophy by 191 
measuring the expression of the protein marker MAFbx/atrogin-1 (Fig.2). When compared to 192 
control cells, the basal level of expression of MAFbx/atrogin-1 decreases after treatment with 193 
polyphenol and tocopherol extracts while, as expected, increases after Dexa addition (Fig.2A). In 194 
contrast, the treatment with polyphenol extract induces, whereas with tocopherol extracts reduces 195 
the MAFbx/atrogin-1 levels in atrophy-induced cells (Fig.2A). A significant reduction of  ubiquitin 196 
ligase content is also found in serum-starved cells treated with total tocopherol (Fig.2B and 197 
polyphenol extract (Fig.2C). Successively, we have investigated the effect of pure γ-tocopherol, the 198 
main tocopherol found in chestnuts. Treatment with γ-tocopherol (24 nM) has a different effect 199 
compared to that promoted by total tocopherol extract on atrophic myotubes (Fig.2D). Indeed, the 200 
addition of the pure compound increases 3.1-fold the expression of MAFbx/atrogin-1 in control 201 
cells, whereas, added to Dexa-treated cells, it slightly reduces the expression of the atrophy marker 202 
(Fig.2D, see also 5A). 203 
 204 
Effect of total polyphenol and tocopherol extracts on protein synthesis in C2C12 myotubes  205 
 206 
In order to quantify the effect of polyphenol and tocopherol extracts on cell muscle atrophy we have 207 
also measured the incorporation of [
3
H]-leucine into proteins (Table 5) in both starved- and Dexa -208 
treated cells in the presence and absence of  total extracts. The incubation with Dexa for 24  hours 209 
does not modify the incorporation of radioactivity into proteins in respect to control cells, whereas 210 
both polyphenol and tocopherol extracts increase it by approximately 1.7-fold and 2.0-fold, 211 
respectively, in agreement with their role in the promotion of myogenic program. The incubation 212 
with both Dexa and polyphenol extract does not significantly changes incorporation of [
3
H]-leucine 213 
into proteins compared to polyphenol extract alone, but radioactivity content remains significantly 214 
different from Dexa-treated myotubes. In contrast, treatment with both Dexa and tocopherol extract 215 
changes protein radioactivity to 1.40-fold and 0.66-fold compared to Dexa and tocopherol-treated 216 
cells, respectively. Serum starvation induces a 48% reduction in the incorporation of radioactivity 217 
into proteins. In this experimental condition, the presence of tocopherol extract increases [
3
H]-218 
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leucine incorporation (1.37-fold), whereas polyphenol extracts do not significantly change protein 219 
synthesis rate compared to control cells. However, both extracts are able to prevent the effects of 220 
serum starvation.   221 
  222 
Effect of polyphenols and tocopherols on skeletal muscle cell autophagy 223 
 224 
Since autophagy is reported to be involved in protein breakdown in skeletal muscle atrophy, we 225 
have also analyzed the morphology of C2C12 myotubes following treatment with Dexa alone and in 226 
combination with total polyphenol or tocopherol extracts, and quantified the relative expression of 227 
Beclin-1, a known autophagic marker (Fig. 3). Notably, the treatment of atrophic myotubes with 228 
Dexa and polyphenol extract, but not tocopherol extract, leads to the appearance of 229 
autophagosomes, a hallmarker of autophagy and to an additive effect on Beclin-1 expression 230 
compared to Dexa alone. Total tocopherol extract does not prevent Dexa-induced autophagy. 231 
 232 
Involvement of ERK1/2 on γ- tocopherol action 233 
 234 
In order to have an insight into the mechanism of action of tocopherol, we have incubated C2C12 235 
myotubes with γ-tocopherol and we have studied the activation of ERK1/2, recently reported to be 236 
an upstream regulator of Atrogin-1
25
. As reported in Fig. 4, in the presence of Dexa, γ-tocopherol is 237 
able to increase the level of phospho-ERK1/2, the active form of this MAPK, supporting a role of 238 
pure compound in the activation of ERK1/2 signaling. 239 
 240 
Effect of sphingolipids on Dexa-induced skeletal muscle cell atrophy  241 
 242 
Finally, we have investigated whether SL extract is able to modify the expression of the atrophy 243 
protein marker MAFbx/atrogin-1. As shown in Fig. 5A, although SL extract does not have any 244 
significant effect on the basal level of the atrophy protein, it is able to prevent the effect of Dexa, 245 
decreasing MAFbx/atrogin-1 levels of approximately 40% , similarly to what observed with total 246 
tocopherol extract (Fig. 3A), but not with γ-tocopherol (Fig. 3C and 5A).   247 
Among the SLs, it is reported that the bioactive lipid S1P, derived from sphingosine kinase 248 
(SK) activation, plays a crucial role as trophic survival factor in skeletal muscle
19-20
. In order to 249 
investigate whether skeletal muscle cell atrophy is correlated to S1P content, we have treated 250 
C2C12 myotubes with the SK inhibitor compound II (iSK)
41
  (Fig. 5B).  We have observed that the 251 
inhibition of S1P generation promotes MAFbx/atrogin-1 expression, and slightly reduces Dexa 252 
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effect. In contrast, serum deprivation does not have any effect on the up-regulation of 253 
MAFbx/atrogin-1 expression elicited by iSK.  254 
255 
 10 
Experimental  256 
 257 
Materials and chemicals  258 
 259 
  Chemicals, standards, cell culture reagents, Dulbecco’s Modified Eagle’s Medium 260 
(DMEM), fetal calf serum (FCS), protease inhibitor cocktail, bovine serum albumin,  horse serum 261 
(HS) and dexamethasone (Dexa) were purchased from Sigma (St. Louis, MO, USA); C2C12 cells 262 
were obtained from American Type Culture Collection (ATCC CRL1772, Manassa, VA, USA); 263 
Coomassie Blue reagent was from Bio-Rad (Hercules, CA, USA); D-erythro-Sphingosine 1-264 
phosphate (S1P) was from Calbiochem (San Diego, CA,USA); tocopherol set was obtained from 265 
Sigma (St. Louis, MO, USA). Sphingosine kinase inhibitor (SKI-II) was from Tocris (Bristol, UK); 266 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit was from Promega (Promega 267 
Madison, WI, USA); penicillin/streptomycin were from Invitrogen (Carlsbad, CA, USA); anti-268 
MAFbx/atrogin-1 antibody, anti-beclin, anti-phospho-ERK1/2 antibodies from Cell Signalling 269 
(Danvers, MA, USA); (C20); anti-myogenin, anti-caveolin-3, anti--actin antibodies and secondary 270 
antibodies conjugated to horse radish peroxidase were from Santa Cruz (Santa Cruz Biotechnology, 271 
CA, USA); L-[3,4,5-
3
H]-Leucine ([
3
H]-leucine), (3.7-5.56 TBq/mmol) was from Perkin Elmer 272 
(Monza, Italy). Enhance chemiluminescence kit (Luminata Western HRP) were from Millipore 273 
(Merck Millipore Headquarters Billerica, MA) and high-performance chemiluminescence film was 274 
from GE Healthcare Life Sciences (Chalfont St. Giles, UK). 275 
 276 
Sample preparation 277 
 278 
 Flours directly furnished by 12 producers from 7 different area of Tuscany (Supplemental 279 
data) immediately after milling have been kept at 16 ± 2°C till the time of analysis. Table 1 280 
describes the areas of origin, the varieties of the fruits and the characteristics of the chain of 281 
production such as the mode of essication (wood essicator “metato” or air oven) the temperature 282 
and time of essication, and the type of mill (stone, or hammer, water mill or electrical mill). 283 
 284 
Traditional drying 285 
 286 
The drying of chestnuts and/or marrons  has represented for centuries the most common method of 287 
transformation of these fruits since it permitted to use the product all year round. The drying 288 
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process is still carried out in a traditional structure called “metato”, located directly in the orchards 289 
or close to the producer’s house (Supplemental Material). 290 
The “metato” is a rectangular structure built in stone without using cement (the so called “a 291 
secco” technique: dry-stone technique). The only room is divided, at half height, by a layer of 292 
chestnut wooden boards. Through a window, located on the higher part of the structure, fruits are 293 
introduced and placed on the boards, ready for drying. Normally a 30 cm thick layer of chestnuts is 294 
left on the wooden board to be dried. In the lower part of the structure a fire exclusively made of 295 
chestnut wood and chaff is lighted. The fire must be rigorously kept without flame in order to 296 
maintain a constant heating of 35ºC-40ºC. The drying process lasts about 40 days. Considering that 297 
the loading into the “metato” is carried out progressively during the harvest, it is important to turn 298 
over the chestnuts each time (or on a weekly basis) a new load is added so that the fresh fruits are 299 
always placed as close as possible to the heat. After drying, the fruit is mechanically separated from 300 
the skin and the pellicle (threshing). The threshing is followed by a fruit selection for a further 301 
quality control.  302 
 303 
Flour preparation 304 
In some samples, grinding is carried out with traditional millstones and other samples have been 305 
obtained with modern techniques using heat pumps, thresher drums and hammer mills that improve 306 
the productivity. After the collection, the chestnut flour were analyzed as described in
29-30
. 307 
 308 
Determination of chestnut and chestnut flour chemical composition  309 
 310 
The moisture content was determined by drying in an oven at 103°C for 6 h as described in Bellini 311 
et al.
29
  The total nitrogen was quantified using the Kjeldahl method and the percentage of nitrogen 312 
was transformed into proteins by using the conversion factor of Mc Carthy (Nx5.3)
29
.  313 
For the fat determination, the sample was hydrolyzed by heating in the presence of 25% 314 
hydrochloric acid. The acidic solution, mixed with ethyl alcohol, was then extracted with ethyl ether 315 
and petroleum ether. The solvent was removed and the fat residue weighed
29
. For the evaluation of 316 
the percentage of saturated, monounsaturated and polyunsaturated fatty acids, fat extract was cooled 317 
and transesterified in the presence of potassium hydroxide methanolic solution. The methyl esters 318 
were separated by GC with FID detector and expressed as % m/m.  319 
The determination of sucrose, fructose and glucose was carried out on the pulp of the fruit of 320 
flour by extraction in water, sonication of the solution (power 50-60%, room temperature) for 30 321 
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minutes and HPLC analysis (mobile phase acetonitrile: water 80:20, quaternary amine column 322 
Spheri Amino-5, 5μm  4.6 x 220 mm, refractive index detector)29.  323 
Determination of starch content was performed using the enzymatic kit from Boeringer 324 
Mannheim (Roche .Daemstadt, Germany). Ash analysis was conducted after  incineration of 325 
samples at 525°C for approximately 8 h. For the determinations of metals, ash residues were 326 
dissolved in 1% nitric acid solution. The solutions were then analyzed by atomic absorption 327 
spectrophotometer Spectr AA220 (Varian, Polo Alto, USA).
29 
328 
 329 
Preparation of phenolic extracts 330 
 331 
A 20 g sample was weighed in a centrifugal tube and then added to 70 ml of  80 % methanol 332 
solution. The suspension was extracted in a ultrasonic bath for 15 min (90 % intensity,  room 333 
temperature) in order to obtain better efficiency in the destruction of cell walls that contained 334 
phenolic compounds. The extract was separated by vacuum filtration and then transferred into a 100 335 
ml flask, adding the necessary volume of deionized water to bring it to 100 ml. That solution was 336 
transferred into 250 ml round-bottom conical flask, added with 11 ml of hydrochloric acid at 37%, 337 
then hydrolyzed for 2 h at 90 °C to obtain aglycone form of the phenols. When the extract was cool, 338 
it was adjusted to pH 7.0  with sodium hydroxide 6 M and the volume was brought to 200 ml with 339 
80% methanol
31
.  340 
 341 
Estimation of total phenolic content 342 
  343 
The total phenolic content of the extracts was determined with Folin-Ciocalteu colorimetric 344 
reaction
32
. External calibration curve were performed using gallic acid as a standard. Five hundred 345 
l of the phenolic extract and 2.5 ml of Folin-Ciocalteau reagent (diluted 1:10) were placed into a 5 346 
ml flask and then, after 2 minutes, taken up to 5 ml with 75 g/l  Na2CO3. The solution was mixed 347 
and incubated at 50 °C for 15 minutes. After cooling, absorbance was measured at 760 nm using a 348 
UV-VIS Cary 1-E spectrophotometer (Varian, Palo Alto, USA). 349 
 350 
Estimation of total flavonoid content 351 
 352 
Strata-X 6 ml/500 mg SPE cartridge (Phenomenex, Macclesfield, United Kingdom) was activated 353 
in order with 10 ml of ethyl acetate, 10 ml of methanol and 10 ml of 0.01 M hydrochloric acid. 10 354 
ml of the phenolic extract were filtered through 0.45 µm RC syringe filter. 5 ml of the filtrate were 355 
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loaded into activated cartridge. 6 ml of 0.01 M hydrochloric acid were flushed through cartridge 356 
and then discarded. 40 ml of ethyl acetate were used to elute the flavonoid fraction. Flavonoid 357 
fraction obtained from SPE treatment was evaporated to dryness on a rotary evaporator, then 358 
dissolved in 10 ml of 80% methanol. Aluminum chloride colorimetric method was used for 359 
determination of flavonoids
33
. Seventy five l of 50 g/lsodium nitrite were added to 2 ml of extract 360 
(appropriately diluted). Aluminum chloride (0.15 ml of 100 
 
g/l) was added after 5 min; 0.5 ml of 1 361 
M sodium hydroxide and 0.25 ml of water were added 6 min later. Absorbance was measured at 362 
510 nm, using UV-VIS Cary 1-E spectrophotometer (Varian, Palo Alto, USA).  External calibration 363 
curve was performed using quercetin as standard.  364 
 365 
Preparation of tocopherol and sphingolipid extracts   366 
 367 
The tocopherol extract was prepared performing the saponification procedure
34
 that consists of 368 
mixing in a 250 ml round-bottom conical flask 20 g flour with a solution containing 30 ml absolute 369 
ethanol, 60 ml of 500 g/l  potassium hydroxide, 15 ml of 100 g/l ascorbic acid and 30 ml sodium 370 
chloride saturated solution. The round flask were equipped with a reflux condenser and then heated 371 
at 70°C for 45 min. After cooling, the saponified mixture was extracted three times with 100 ml of 372 
10% ethyl acetate in hexane. Extracts were collected and filtered through anhydrous Na2SO4. The 373 
extract was evaporated to dryness and reconstituted in 8 ml of heptane.  374 
SL extracts were prepared from chestnut flours obtained from the specific areas. The sample 375 
was weighed in a screw tube and then added to 5 ml of CHCl3: MeOH (1:2). The suspension was 376 
extracted in a ultrasonic bath for 10 min. The mixture was then incubated at 37.5 °C for 1 h in a 377 
closed screw tube, cooled down to room temperature and filtered. Saponification, used to remove 378 
phospholipids and neutral lipids from SLs, was performed using 1 M KOH for 6 h at 40°C with 379 
stirring, and successively the samples were neutralized and washed using the method of Folch et al. 380 
35
. After solvent partition of SLs, HP-TLC analysis was performed accordingly to standardized 381 
procedures with some modifications
36
. Briefly, the plates (silica gel 60) were activated for 30 min at 382 
120°C before use. Standards and reconstituted samples were applied onto the plate with a 383 
microdispenser and plate developed with mobile phase (chloroform:methanol:water, 65:25:4). To 384 
quantify each lipid species (SM, cerebrosides, galactosylceramide), calibration curves were 385 
obtained by running in parallel known amounts of purified lipid standards. The plates were 386 
visualized with sulfuric acid-CuSO4-ammonium molybdate spray reagent followed by heating at 387 
110°C for 15 min (SM) or with 3% cupric acetate in 8% phosphoric acid solution for 10 min at 388 
180°C (ceramide) or with 0.5% α-naphthol in methanol-water, 1:1, dried at room temperature, 389 
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sprayed with sulfuric acid- water, 95:5, and heated at 100°C. Densitometry of standard and sample 390 
zones was performed and the SLs content determined by interpolation from the graph.  391 
 392 
Estimation of total tocopherols content 393 
 394 
Tocopherols were quantified according to the official NF ISO method 9936
37
 by high-performance 395 
liquid chromatography (HPLC-1100 series, Hewlett-Packard) equipped with fluorescence detector 396 
(excitation  295 nm, emission  330 nm). Analysis of tocopherols was performed using a 397 
thermostated Phenomenex Luna silica column (25 cm × 4.6 mm i.d. × 5 μm), at 25 °C, with the 398 
corresponding analysis guard column. The HPLC mobile phase consisted of heptane/t-butyl methyl 399 
ether (94:6 v/v), eluted at a flow rate of 1.5 ml/min. 400 
 401 
Cell culture and treatments 402 
 403 
Murine C2C12 myoblasts were routinely grown in DMEM supplemented with 10% FCS. For 404 
myogenic differentiation experiments, cells were grown in until 95% of confluency and induced to 405 
differentiate by switching to differentiation medium (DM), DMEM containing 1-2% horse serum 406 
(HS) for the  following 3-5 days. To obtain the phenotype of atrophic cells, C2C12 myotubes (MT) 407 
were maintained in a culture medium free of nutrients and growth factors (-FCS, starvation) for 24-408 
48 hours, or treated with Dexa, a compound which enhances the degradation of proteins
25
.  409 
The analysis of the atrophic phenotype was performed a) by evaluating cell morphology 410 
under a phase contrast microscope and quantifying the number of myonuclei and the cell diameter 411 
(fiber size), b) by a molecular approach consisting in the evaluation by Western Blotting analysis of 412 
the expression of MAFbx/Atrogin-1, the ubiquitin ligase typically expressed in atrophic cells
24
.  413 
 414 
LDH activity determination 415 
Cell toxicity was determined by lactic dehydrogenase (LDH) activity release in cell medium. 416 
Positive control of cell lysis was performed adding 0.1% Triton X 100 for 30 min to cell monolayer. 417 
Values were expressed as mean % ±SD of two independent experiments, each at least in duplicate.  418 
 419 
Viability MTS  assay  420 
 421 
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-422 
sulfophenyl)-2H-tetrazolium (MTS) assay
20
. Briefly, C2C12 cells in 96-well plates were plated at 423 
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50% confluence and synchronized in serum-free medium for 24 h. Then, cells were incubated in 424 
medium containing 10% FCS, and treated with bioactive molecules or specific inhibitors for the 425 
indicated times and incubated for further 24 h. MTS assay kit was utilized to measure production of 426 
formazan, which is directly proportional to the cell viability. Optical density at 490 nm wavelenght 427 
was determined using an ELISA microplate reader (Bio-Rad, Hercules, CA, USA).  428 
 429 
Protein synthesis measurement by [
3
H]-leucine incorporation 430 
 431 
To measure the rate of protein synthesis, C1C12 differentiated cells (24-well plates), treated or not 432 
with Dexa or starved as indicated for each specific experimental condition,  were incubated in Leu-433 
labeling medium RPMI (without Leu), and labeled with 0.037 MBq /ml of [
3
H]-leucine for 2 hours. 434 
At the indicated time points, the monolayer was washed with phosphate buffered saline and 435 
incubated in ice cold 10% trichloroacetic acid (TCA) for 30 min at 4°C. The TCA-precipitable 436 
material was washed with cold 5% TCA, and then solubilized in 0.1 M NaOH. [
3
H]-leucine 437 
incorporation was measured by liquid scintigraphy in a beta counter (Beckman). Decays per minute 438 
(DPM) were normalized by total protein for each well.  439 
 440 
Western blotting analysis 441 
 442 
Immunoblotting was performed using enhanced chemiluminescence as previously reported
27, 38
. 443 
Cells were lysed for 30 min at 4 C in a buffer containing 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 444 
1 mM EDTA, 6 mM EGTA, 15 mM Na4P2O7, 20 mM NaF, 1% Nonidet and protease inhibitor 445 
cocktail (1.04 mM AEBSF, 0.08 M aprotinin, 0.02 mM leupeptin, 0.04 mM bestatin, 15 M 446 
pepstatin A, 14 M E-64) essentially as described in38. Cell extracts were centrifuged for 15 min at 447 
10,000xg at 4 C. Proteins (10-25 g) from lysates were resuspended in Laemmli’s sodium 448 
dodecylsulfate (SDS) sample buffer. Samples were subjected to SDS-polyacrylamide gel 449 
electrophoresis (SDS-PAGE) and Western Blotting analysis as previously described
38
. The blots were 450 
first blocked in 5% milk in Tris-buffered saline with 0.1% Tween 20 (TBST) at room temperature 451 
for 1 h, and then incubated in the same blocking solution containing primary antibodies overnight at 452 
4°C. After sufficient washes with TBST, blots were incubated with appropriate horseradish 453 
peroxidase-conjugated secondary antibodies for 1 h. Blots were again washed in TBST and, 454 
thereafter, signals were detected by using Luminata Western HRP reagent. Finally, blots were 455 
exposed to high-performance chemiluminescence film. Densitometric analysis of the bands was 456 
performed using NIH IMAGE (ImageJ software, Bethesda, MD, USA) and Quantity-One (Imaging 457 
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and Analysis Software by Bio-Rad Laboratories, Hercules, CA) and band intensity was reported as 458 
relative percentage (means  SEM), obtained by calculating the ratio of specific protein on -actin 459 
or -tubulin intensity and normalizing to control, set as 100.  460 
 461 
Statistical analysis 462 
 463 
For all the experiments at least three samples were analysed and all the assays were carried out in 464 
triplicates. The results are expressed as range of mean values and standard error (S.E.M.) or 465 
standard deviation (S.D.). The differences between the chestnut extracts were analysed using one-466 
way analysis of variance (ANOVA), considering statistical significant  P < 0.05.467 
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Discussion 468 
 469 
The present study points out that tuscan chestnut sweet flour is a natural source of specific 470 
bioactive components (tocopherols and SLs) able to counteract the degenerative processes (atrophy 471 
and autophagy) responsible for the loss of skeletal muscle mass. The basic composition and 472 
nutraceutical properties of sweet chestnut flours obtained from fruits collected from 7 different 473 
areas of Tuscany (Italy) were found to be very similar; the differences seemed to be dependent on 474 
several parameters from the methodologies used to obtain the flours to the tipology of cultivar or 475 
regions of origin. The chemical composition was also similar to that published for fruits of other 476 
territorial origins reviewed in
6
. In the present manuscript, we also show the vitamin E profile that 477 
appears to be similar along all the assayed tuscan sweet chestnut flours (γ-tocopherol > δ-tocopherol 478 
> α-tocopherol > -tocopherol), and to what has been reported from other chestnut fruits4.  479 
It is worth noting that the content in tocopherols measured in sweet chestnut flours (18-114 480 
mg/kg) is higher than that found in fruits by Barreira et al.,
4
 and de Vasconcelos et al.
6
,  that have 481 
reported a value of 4 and 4-27 mg/kg for Portuguese chestnuts, respectively, likely due to the loss of 482 
water during flour preparation, or other factors such as harvesting year, sampling or methodological 483 
analytical procedures.  484 
Although almonds, hazelnuts, walnuts, pistachios and pecans are not generally used to 485 
produce flour, the comparison between the composition of chestnut flours and these fruits indicates 486 
a quite dissimilar qualitative vitamin E profile from almond or hazelnut, but very similar to that 487 
obtained from walnut, pistachios or pecans
42
.  488 
The high γ-tocopherol dominance in chestnut flour may represent an important feature for 489 
the nutraceutical properties of this product, since γ-tocopherol is known to be the most effective 490 
isoform in scavenging free radicals and nitrogen oxygen species and to have anticancer and anti-491 
inflammatory action
1, 43
.  492 
Table 3  indicates that γ-tocopherol content was in the same range for all geographic areas 493 
considered (89-96%). We have found some statistical differences in γ-tocopherol content among the 494 
analysed samples, also of the same area, suggesting an influence of the drying parameters in 495 
preserving the content of bioactive compounds.   496 
Numerous studies performed using animal models have confirmed that prolonged skeletal 497 
muscle inactivity/or atrophic conditions promote  oxidative stress, leading to an increase of reactive 498 
oxygen species (ROS) produced in both inactive and contracting skeletal muscles. When ROS 499 
production in cells exceeds the antioxidant capacity to maintain the normal redox balance, a pro-500 
oxidant state occurs  altering redox signaling.  501 
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The here reported findings demonstrate that long-term incubation with chestnut flour 502 
tocopherol and polyphenol extracts decreases myoblast proliferation. Since no apoptotic hallmarks 503 
are found, the decrease in cell growth appears due to cell cycle arrest and, likely, in the induction of 504 
myogeneic differentiation (E.M., personal communication).  505 
A growing number of in vitro studies reveal that selective antioxidants can delay disuse 506 
muscle atrophy. Notably, it is worth noting that total tocopherol extracts from tuscan chestnut sweet 507 
flour protect from skeletal muscle cell atrophy and this protection appears not to be due to a general 508 
antioxidant action, since the total polyphenol extract, that are also considered antioxidants, fails to 509 
protect C2C12 cells either from changes in morphology than from reduction in protein synthesis. In 510 
addition, chestnut flour tocopherol extract does not affect Dexa-induced autophagy, whereas, 511 
polyphenol extract potentiates the effect of Dexa on Beclin-1 expression and on the acquisition of 512 
an autophagic phenotype, indicating a more severe cytotoxic effect after treatment with this latter 513 
bioactive molecule. Notably, although both total tocopherol extract and γ-tocopherol can prevent 514 
Dexa-induced atrophy, each of the compounds differently affects Atrogin-1 expression. In 515 
particular, pure γ-tocopherol alone increases expression of the atrophy marker MAFbx/atrogin-1 516 
and alters cell morphology in accordance with recent studies that have cast doubt on the benign 517 
effects of long-term antioxidant supplementation
44. In contrast, although γ-tocopherol accounts for 518 
more than 90% of the tocopherol extracts, the latter has a positive effect both in control and in 519 
atrophic myotubes. On the other hand, the total extract may contain other marginal compound(s) 520 
responsible for the beneficial effects. 521 
Therefore, tocopherol mixtures, obtained from natural products, might offer beneficial advantages 522 
in some patients and in aging populations because they possess enhanced anti-inflammatory activity 523 
compared to pure compounds, as also reported in various studies1,43. Moreover, the properties of 524 
tocopherol chestnut extracts likely able to counteract ROS-mediated processes and/or directly exert 525 
antioxidant effects, might be useful for ameliorating skeletal muscle performance. This in vitro 526 
study needs to be confirmed in animal models since the bioavailability of the active compounds 527 
could preclude the putative beneficial effects. Moreover,  the translation from animal models to 528 
humans, already occurred for other molecules such as curcumin, will allow to address the 529 
pharmacokinetics, safety, and efficacy of this nutraceutical in human health. Since chestnust flour is 530 
a gluten-free flour, the nutraceutical properties reported in this study and others
5-9
 allows to 531 
consider this functional food as a part of a diet for people affected by coeliac disease.  532 
A novel and relevant finding of the present study is the presence of SLs in chestnut flour and 533 
the protective role played by SLs extracts on skeletal muscle cell atrophy. Although, SLs represent 534 
an important source of bioactive molecules, only a few of the published studies reported the 535 
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analysis of their content in food, found to be some hundreds of mg/kg
17
. The content of SLs 536 
approximately 50 mg/kg dry weight is a relatively low concentration, but appears to be sufficient  to 537 
prevent MAFbx/atrogin-1 expression.  538 
SLs are first and/or second messengers involved in the regulation of cell fate, inflammation 539 
and migration
18
 and are known to play an important role in maintaining cellular redox homeostasis 540 
through regulation of NADPH oxidase, mitochondrial integrity, and antioxidant enzymes
45
. It is 541 
worth noting that diseases which result in muscle weakness, such as heart failure, are characterized 542 
by alteration in SLs metabolism
46
: elevated sphingomyelinase (SMase) activity that, in intact 543 
muscle, increases mitochondrial ROS that contribute to diminished muscle force
47
.   544 
Bioactive SLs (ceramide, S1P and ceramide-1-phosphate) play a crucial role in skeletal 545 
muscle cell biology, and, since they are interconvertible molecules
18,46
, they often exhibit opposite 546 
actions also in skeletal muscle cells
26,36
: S1P is a prosurvival and promyogenic factor
19-21
 whereas 547 
ceramide inhibits myogenesis
48
.  548 
The characterization of the specific bioactive lipids of chestnut extracts able to affect 549 
myotube atrophy, was not an aim of the present work. However, on the basis of the relevance of 550 
these compounds for the physiopathology of many tissues, it will be worthy to be investigated. 551 
The here reported protective effect might be mediated by S1P since in our experimental 552 
conditions SK inhibitor increases the expression of the atrophy marker Atrogin-1/MAFbx, and 553 
decreases the nuclei number and cell diameter (E.M., personal communication), supporting a 554 
positive role of SK/S1P axis on the maintenance of a normal differentiated skeletal muscle 555 
phenotype.  Whether the protective effect of chestnut sweet flour SL extracts is due to the specific 556 
bioactive lipid S1P and whether it is related to maintenance of redox homeostasis or to a different 557 
mechanism is worth to be further investigated. Indeed, it might help to clarify the nutraceutical 558 
properties relevant for skeletal muscle mass regulation and to address an important question on 559 
which conditions, in the chestnut flour chain of production (methodological, industrial, etc.) must 560 
be kept under control to assure the preservation of these nutraceutical properties. 561 
Moreover, since many studies have suggested that a low vitamin E nutritional status and the 562 
level of SLs in plasma are associated with pathological condition
49-51
, a diet enriched in natural 563 
products containing tocopherol and SL extracts might be advantageous for maintaining a healthy 564 
status and wellness.  565 
 566 
Conclusion 567 
 568 
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The present work provide the first evidence that chestnut sweet flour is a source of specific 569 
bioactive components, such as tocopherols and SLs, with a relevant role in the prevention of cell 570 
degeneration and maintaining of skeletal muscle mass. Therefore, these observations might be 571 
useful in designing appropriate nutritional therapeutical approaches in skeletal muscle cell atrophy, 572 
consisting in a diet enriched of food naturally rich in SLs or developing products fortified with SLs 573 
that may be of help for an aged population that undergo to a physiological decrease of skeletal 574 
muscle mass and tone. 575 
576 
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 732 
LEGENDS 733 
 734 
Fig. 1. Effect of total polyphenol and tocopherol extracts on skeletal muscle cell growth.  735 
 736 
A) Cell counting. C2C12 cells were serum-starved for 24 h and, successively, incubated in growth 737 
medium in the absence or in the presence of vehicle (control), polyphenols (100 nM) or tocopherols 738 
(100 nM) for the indicated time (days). Cells were collected by tripsinization and counted using 739 
Burker camera. Values are means  S.E.M. of at least three independent experiments performed in 740 
quadruplicate (*P < 0.05 vs. vehicle). 741 
B) MTS-dye reduction assay. C2C12  cells were treated as above and formazan product was 742 
quantified by reading optical density at 490 nm. Values are means  S.E.M. of three independent 743 
experiments performed in quadruplicate (*P < 0.05 vs. vehicle t0,
 §
P<0.05 vs. specific control).  744 
 745 
Fig. 2.  Effect of polyphenol and tocopherol extracts on skeletal muscle cell atrophy.  746 
 747 
A-D) Western blot analysis of MAFbx/atrogin-1 (Atrogin-1) expression.  C2C12 myotubes were 748 
incubated with vehicle or with polyphenol or tocopherol extracts (100 nM) for 1 hour before the 749 
addition of Dexa (A) or serum-starved as indicated (B,C) or treated with γ-tocopherol (24 nM) as 750 
indicated in (D).  Thirty six hours later, cells were harvested and  lysed as described in Methods.  751 
Total lysates (20 g) were used to immunodetect the level of MAFbx/atrogin-1 with specific 752 
antibodies and revealed by enhanced chemoluminescence. Equally loaded protein was checked by 753 
expression of the non-muscle specific  isoform of actin. The band intensity is reported in the 754 
graphics as percentage relative to the intensity of the band corresponding to the respective 755 
unchallenged control set as 100. Values are means  S.E.M. of three independent experiments (*P < 756 
0.05 vs control (vehicle) in 3A and 3D or serum starvation (-FCS) in 3B and 3C, §P<0.05 vs. Dexa).   757 
 758 
Fig. 3.  Effect of polyphenols and tocopherols on skeletal muscle cell autophagy.  759 
 760 
A) Images of a representative field were obtained by phase contrast microscopy. C2C12 myotubes 761 
(MT) were treated in the presence or absence of total polyphenol or tocopherol  extracts before the 762 
addition of Dexa. Note in the magnification the typical autophagic vacuoles. 763 
B) Western Blotting analysis. C2C12 differentiated cells were treated as in A). Twenty-four hours 764 
later, myotubes were harvested and lysated as described in Methods. Specific antibodies were used 765 
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to immunodetect Beclin-1 (Beclin), revealed by enhanced chemoluminescence. Equally loaded 766 
protein was checked by evaluating the expression level of -actin. Band intensity is reported in the 767 
graphic as percentage relative to the intensity of the band corresponding to the respective 768 
unchallenged control set as 100. Values are means  S.E.M. of at least three independent 769 
experiments (Student’s t test *P < 0.05 vs. Dexa). 770 
 771 
Fig. 4. Involvement of ERK1/2 on γ-tocopherol action.  772 
 773 
Western blot analysis of phospho-ERK1/2 expression was performed using C2C12 myotubes 774 
incubated with vehicle or with γ-tocopherol (-Toco) for 1 hour before the addition of Dexa  as 775 
indicated. Thirty six hour later, cells were harvested, lysed and total lysates (20 g) immunoblotted 776 
to detect the level of the active form of ERK1/2 (phospho-ERK1/2, p-ERK1/2). Band intensity 777 
corresponding to p-ERK was normalized on the value of -actin and it is reported in the graphic as 778 
percentage relative control set as 100.  Values are means  S.E.M. of at least three independent 779 
experiments (Student’s t test, *p 0.05 vs. control (vehicle). 780 
 781 
Fig. 5 Effect of sphingolipid extract on skeletal muscle cell atrophy.  782 
 783 
A) Western blot analysis of MAFbx/atrogin-1 (Atrogin-1) expression. C2C12 myotubes were 784 
incubated with vehicle or with total SLs extract for 1 hour before the addition of Dexa  or treated 785 
with γ-tocopherol (24 nM) as indicated. Thirty six  hours later, cells were harvested and  lysed as 786 
described in Methods. Total lysates (20 g) were used to immunodetect the level of 787 
MAFbx/atrogin-1 (Atrogin-1).  788 
B) Western blot analysis of MAFbx/atrogin-1 (Atrogin-1) expression. C2C12 myotubes were 789 
incubated with vehicle or with sphingosine kinase inhibitor (iSK) for 1 hour before the addition of  790 
Dexa or serum-starved as indicated. Thirty six  hour later cells were lysed and MAFbx/atrogin-1 791 
immunodetected. Equally loaded protein was checked by expression of the non-muscle specific 792 
protein (-actin or -tubulin).  Band intensity is reported in the graphics as percentage relative to 793 
the intensity of the band corresponding to the respective unchallenged control set as 100. Student’s t 794 
test, *P 0.05 vs. control; #P 0.05  vs. SLs alone (in A) or serum-starved control cells in (B). 795 
